Palbociclib CAS 571190-30-2 Purity >99.5% (HPLC) API Factory

Short Description:

Chemical Name: Palbociclib

CAS: 571190-30-2

Purity: >99.5% (HPLC)

Appearance: White or Off-White Powder

API In the Treatment of Breast Cancer

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Palbociclib Related Intermediates:
Palbociclib CAS 571190-30-2
5-Bromo-2,4-Dichloropyrimidine CAS 36082-50-5
5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8
tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate CAS 571189-16-7
tert-Butyl 4-(6-Amino-3-Pyridyl)piperazine-1-Carboxylate CAS 571188-59-5
6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2
2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4

Chemical Properties:

Chemical Name	Palbociclib
Synonyms	PD-0332991; Otava-Bb 1115529; Ibrance
CAS Number	571190-30-2
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C24H29N7O2
Molecular Weight	447.54
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White or Off-White Powder
1H NMR Spectrum	Consistent With Structure
HPLC	Consistent With Structure
Related Substances
Individual Impurity	<0.50%
Total Impurities	<1.00%
Loss on Drying	<0.50%
Residue on Ignition	<0.10%
Heavy Metals	<10ppm
Purity / Analysis Method	>99.5% (HPLC)
Test Standard	Enterprise Standard
Usage	API, In the Treatment of Breast Cancer

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

Palbociclib (CAS: 571190-30-2) is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. Palbociclib is the first representative of the new drug class of cyclin-dependent kinase inhibitors. This effect limits cell proliferation (cell growth and division). It is used as an antineoplastic agent in advanced or metastatic breast cancer.